Literature DB >> 9498685

Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

A Sparreboom1, P de Bruijn, K Nooter, W J Loos, G Stoter, J Verweij.   

Abstract

An isocratic reversed-phase high-performance liquid chromatographic method with ultraviolet detection at 230 nm has been developed for the determination of paclitaxel in human plasma. Plasma samples were prepared by a selective one-step liquid-liquid extraction involving a mixture of acetonitrile-n-butyl chloride (1:4, v/v). Paclitaxel and the internal standard docetaxel were separated using a column packed with ODS-80A material, and a mobile phase consisting of water-methanol-tetrahydrofuran-ammonium hydroxide (37.5:60:2.5:0.1, v/v). The calibration graph for paclitaxel was linear in the range 10-500 ng/ml, with a lower limit of quantitation of 10 ng/ml, using 1 ml plasma samples. The extraction recoveries of spiked paclitaxel and docetaxel to drug-free human plasma were 89.6+/-8.52 and 93.7+/-5.0%, respectively. Validation data showed that the assay for paclitaxel is sensitive, selective, accurate and reproducible. The assay has been used in a single pharmacokinetic experiment in a patient to investigate the applicability of the method in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498685     DOI: 10.1016/s0378-4347(97)00502-1

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  12 in total

1.  Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial.

Authors:  Mary Cianfrocca; Sandra Lee; Jamie Von Roenn; Michelle A Rudek; Bruce J Dezube; Susan E Krown; Joseph A Sparano
Journal:  Cancer Chemother Pharmacol       Date:  2011-01-05       Impact factor: 3.333

2.  4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

Authors:  Anne-Joy M de Graan; Alex Sparreboom; Peter de Bruijn; Evert de Jonge; Bronno van der Holt; Erik A C Wiemer; Jaap Verweij; Ron H J Mathijssen; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2015-08-12       Impact factor: 4.335

3.  A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).

Authors:  Sophie Callies; Dinesh P de Alwis; Adrian Harris; Paul Vasey; Jos H Beijnen; Jan H Schellens; Michael Burgess; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

4.  Effect of valspodar on the pharmacokinetics of unbound paclitaxel.

Authors:  Albert J ten Tije; Timothy W Synold; Darcy Spicer; Jaap Verweij; James H Doroshow; Alex Sparreboom
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

5.  CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

Authors:  Anne-Joy M de Graan; Laure Elens; Jason A Sprowl; Alex Sparreboom; Lena E Friberg; Bronno van der Holt; Pleun J de Raaf; Peter de Bruijn; Frederike K Engels; Ferry A L M Eskens; Erik A C Wiemer; Jaap Verweij; Ron H J Mathijssen; Ron H N van Schaik
Journal:  Clin Cancer Res       Date:  2013-05-02       Impact factor: 12.531

6.  Pharmacokinetic evaluation of Paclitaxel in South Indian cancer patients: a prospective study.

Authors:  J Vasantha; G Kannan; T Goud; T Palani; R Vanitha; R Anitha; Jmm Priya
Journal:  J Young Pharm       Date:  2011-10

7.  High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection.

Authors:  Anders Andersen; David J Warren; Paal F Brunsvig; Steinar Aamdal; Gunnar B Kristensen; Harald Olsen
Journal:  BMC Clin Pharmacol       Date:  2006-01-13

8.  Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.

Authors:  Bo Gao; Yi Lu; Annemieke J M Nieuweboer; Hongmei Xu; Jonathan Beesley; Ingrid Boere; Anne-Joy M de Graan; Peter de Bruijn; Howard Gurney; Catherine J Kennedy; Yoke-Eng Chiew; Sharon E Johnatty; Philip Beale; Michelle Harrison; Craig Luccarini; Don Conroy; Ron H J Mathijssen; Paul R Harnett; Rosemary L Balleine; Georgia Chenevix-Trench; Stuart Macgregor; Anna de Fazio
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

9.  A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.

Authors:  V Bozionelou; L Vamvakas; P Pappas; S Agelaki; N Androulakis; A Kalykaki; M Nikolaidou; N Kentepozidis; S Giassas; M Marselos; V Georgoulias; D Mavroudis
Journal:  Br J Cancer       Date:  2007-06-05       Impact factor: 7.640

10.  Development and Validation of a Rapid RP-HPLC-DAD Analysis Method for the Simultaneous Quantitation of Paclitaxel and Lapatinib in a Polymeric Micelle Formulation.

Authors:  Ebrahim Saadat; Fatemeh Ravar; Pouya Dehghankelishadi; Farid A Dorkoosh
Journal:  Sci Pharm       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.